TY - JOUR
T1 - Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers
AU - Halushka, Perry V.
AU - Goodwin, Andrew J.
AU - Halushka, Marc K.
N1 - Funding Information:
M.K.H. was supported by the US National Institutes of Health (grant no. 1R01HL137811) and the American Heart Association (Grant-in-Aid no. 17GRNT33670405). P.V.H. was supported by the US National Institutes of Health (grant nos. UL1TR001450 and 1R01GM113995). A.J.G. was supported by the US National Institutes of Health (grant nos. 1K23HL135263–01A and 1R01GM113995).
Publisher Copyright:
© 2019 by Annual Reviews. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Cardiovascular diseases exist across all developed countries. Biomarkers that can predict or diagnose diseases early in their pathogeneses can reduce their morbidity and mortality in afflicted individuals. microRNAs are small regulatory RNAs that modulate translation and have been identified as potential fluid-based biomarkers across numerous maladies. We describe the current state of cardiovascular disease biomarkers across a range of diseases, including myocardial infarction, acute coronary syndrome, myocarditis, hypertension, heart failure, heart transplantation, aortic stenosis, diabetic cardiomyopathy, atrial fibrillation, and sepsis. We present the current understanding of microRNAs as possible biomarkers in these categories and where their best opportunities exist to enter clinical practice.
AB - Cardiovascular diseases exist across all developed countries. Biomarkers that can predict or diagnose diseases early in their pathogeneses can reduce their morbidity and mortality in afflicted individuals. microRNAs are small regulatory RNAs that modulate translation and have been identified as potential fluid-based biomarkers across numerous maladies. We describe the current state of cardiovascular disease biomarkers across a range of diseases, including myocardial infarction, acute coronary syndrome, myocarditis, hypertension, heart failure, heart transplantation, aortic stenosis, diabetic cardiomyopathy, atrial fibrillation, and sepsis. We present the current understanding of microRNAs as possible biomarkers in these categories and where their best opportunities exist to enter clinical practice.
KW - microRNAs, biomarkers, cardiovascular disease, hypertension, sepsis, aortic stenosis
UR - http://www.scopus.com/inward/record.url?scp=85060540879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060540879&partnerID=8YFLogxK
U2 - 10.1146/annurev-pathmechdis-012418-012827
DO - 10.1146/annurev-pathmechdis-012418-012827
M3 - Review article
C2 - 30332561
AN - SCOPUS:85060540879
SN - 1553-4006
VL - 14
SP - 211
EP - 238
JO - Annual Review of Pathology: Mechanisms of Disease
JF - Annual Review of Pathology: Mechanisms of Disease
ER -